Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells

Biochemical Pharmacology

Volumn 82, Issue 12, 2011, Pages 1884-1890

  Yoshida, Kozue ^a,b,c   Nagai, Tadashi ^a   Ohmine, Ken ^a   Uesawa, Mitsuyo ^a   Sripayap, Piyanuch ^a   Ishida, Yoji ^b   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aurora kinase inhibitor; Leukemia; VE 465; Vincristine

Indexed keywords

ANTILEUKEMIC AGENT; AURORA KINASE INHIBITOR; CASPASE 3; CASPASE 7; CASPASE 9; CHECKPOINT KINASE 2; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG; VE 465; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR SIGNALING; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA, MYELOID; PHOSPHORYLATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; VINCRISTINE;

EID: 80555149278     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.09.015     Document Type: Article

References (27)

1. G.Q. Chen, L.S. Wang, Y.L. Wu, and Y. Yu Leukemia, an effective model for chemical biology and target therapy Acta Pharmacol Sin 28 2007 1316 1324 (Pubitemid 47366677)
2. E. Jabbour, J. Cortes, and H. Kantarjian Treatment selection after imatinib resistance in chronic myeloid leukemia Target Oncol 4 2009 3 10
3. E.A. Sausville Aurora kinases dawn as cancer drug targets Nat Med 10 2004 234 235 (Pubitemid 38667607)
4. J. Fu, M. Bian, Q. Jiang, and C. Zhang Roles of Aurora kinases in mitosis and tumorigenesis Mol Cancer Res 5 2007 1 10
5. G. Vader, and S.M. Lens The Aurora kinase family in cell division and cancer Biochim Biophys Acta 1786 2008 60 72
6. M. Kimura, Y. Matsuda, T. Yoshioka, and Y. Okano Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3 J Biol Chem 274 1999 7334 7340
7. H. Katayama, W.R. Brinkley, and S. Sen The Aurora kinases: role in cell transformation and tumorigenesis Cancer Metastasis Rev 22 2003 451 464 (Pubitemid 36791899)
8. N. Keen, and S. Taylor Aurora-kinase inhibitors as anticancer agents Nat Rev Cancer 4 2004 927 936 (Pubitemid 39626216)
9. R.D. Carvajal, A. Tse, and G.K. Schwartz Aurora kinases: new targets for cancer therapy Clin Cancer Res 12 2006 6869 6875 (Pubitemid 44974478)
10. E.A. Harrington, D. Bebbington, J. Moore, R.K. Rasmussen, A.O. Ajose-Adeogun, and T. Nakayama VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Nat Med 10 2004 262 267 (Pubitemid 38667616)
11. T.A. Carter, L.M. Wodicka, N.P. Shah, A.M. Velasco, M.A. Fabian, and D.K. Treiber Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc Natl Acad Sci USA 102 2005 11011 11016 (Pubitemid 41105984)
12. M.A. Young, N.P. Shah, L.H. Chao, M. Seeliger, Z.V. Milanov, and W.H. Biggs 3rd Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680 Cancer Res 66 2006 1007 1014 (Pubitemid 43168337)
13. T. O'Hare, and M.W. Deininger Toward a cure for chronic myeloid leukemia Clin Cancer Res 14 2008 7971 7974
14. O. Gautschi, J. Heighway, P.C. Mack, P.R. Purnell, P.N. Lara Jr, and D.R. Gandara Aurora kinases as anticancer drug targets Clin Cancer Res 14 2008 1639 1648 (Pubitemid 351471713)
15. F.J. Giles, J. Cortes, D. Jones, D. Bergstrom, H. Kantarjian, and S.J. Freedman MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation Blood 109 2007 500 502 (Pubitemid 46105945)
16. E.C. VanderPorten, P. Taverna, J.N. Hogan, M.D. Ballinger, W.M. Flanagan, and R.V. Fucini The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model Mol Cancer Ther 8 2009 930 939
17. Y. Kano, M. Akutsu, S. Tsunoda, H. Mano, Y. Sato, and Y. Honma In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Blood 97 2001 1999 2007 (Pubitemid 32239079)
18. T. Miyoshi, T. Nagai, K. Ohmine, M. Nakamura, Y. Kano, and K. Muroi Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines Biochem Pharmacol 69 2005 1585 1594 (Pubitemid 40719495)
19. G.G. Steel, and M.J. Peckham Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity Int J Radiat Oncol Biol Phys 5 1979 85 91 (Pubitemid 9120186)
20. T. Nagai, S. Kikuchi, K. Ohmine, T. Miyoshi, M. Nakamura, and T. Kondo Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2 J Cell Biochem 104 2008 680 691 (Pubitemid 351671654)
21. T. Nagai, K. Igarashi, J. Akasaka, K. Furuyama, H. Fujita, and N. Hayashi Regulation of NF-E2 activity in erythroleukemia cell differentiation J Biol Chem 27 1998 5358 5365 (Pubitemid 28108704)
22. Z.Z. Lin, H.C. Hsu, C.H. Hsu, P.Y. Yeh, C.Y. Huang, and Y.F. Huang The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma J Hepatol 50 2009 518 527
23. J.M. Negri, D.W. McMillin, J. Delmore, N. Mitsiades, P. Hayden, and S. Klippel In vivo anti-myeloma activity of the Aurora kinase inhibitor VE-465 Br J Haematol 147 2009 672 676
24. N. Zhu, Y. Shao, L. Xu, L. Yu, and L. Sun Gadd45-alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells Mol Biol Rep 36 2009 2075 2085
25. D.O. Moon, M.O. Kim, Y.H. Choi, J.W. Hyun, W.Y. Chang, and G.Y. Kim Butein induces G(2)/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation Cancer Lett 288 2010 204 213
26. S. Uchida, K. Yoshioka, R. Kizu, H. Nakagama, T. Matsunaga, and Y. Ishizaka Stress-activated mitogen-activated protein kinases c-Jun NH2-terminal kinase and p38 target Cdc25B for degradation Cancer Res 69 2009 6438 6444
27. X. Liu, C. Bian, K. Ren, H. Jin, B. Li, and R.G. Shao Lidamycin induces marked G2 cell cycle arrest in human colon carcinoma HT-29 cells through activation of p38 MAPK pathway Oncol Rep 17 2007 597 603